ERBB2 and breast carcinoma: TLT showed greater tumoricidal activity against BL-CL breast cancers in 8 of 12 breast cancer cell lines (50% effective concentration (EC50) <100 μM) as compared with luminal/Her2+ breast cancer, for which TLT demonstrated similar potency in only 4 of 18 cell lines (Table 1, Figure S5).